RxDoctor Payments Data

Benjamin Peck, MD

Family Medicine · Daytona Beach, FLNPI 1841396769

Payments from drug & device makers

$704in general payments, 2019–2025

Across 25 payments — averaging $28.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$315
  • Bayer$119
  • AbbVie$73
  • GSK$46
  • AstraZeneca$41
  • Amarin Pharma, Inc.$33
  • plus $78 from 4 others

What the payments were for

  • Food & beverage$704100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk5$315
Bayer2$119
AbbVie(2 entities)5$73
GSK2$46
AstraZeneca3$41
Amarin Pharma, Inc.2$33
Johnson & Johnson(2 entities)2$29
Arbor Pharmaceuticals, Inc.2$22
Pfizer1$15
Boehringer Ingelheim1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$704 in reported general payments places this provider in the 55th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$150,144
Medicare patients
340
Services billed
1,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$91,729
OzempicSemaglutide59$65,900
XareltoRivaroxaban21$32,181
JardianceEmpagliflozin26$30,187
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$22,362
JanuviaSitagliptin Phosphate11$17,836
FarxigaDapagliflozin Propanediol12$17,499
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,923
Atorvastatin Calcium556$6,446
Valsartan201$6,283
ProzacFluoxetine Hcl14$5,890
Arnuity ElliptaFluticasone Furoate11$5,768
VascepaIcosapent Ethyl14$5,044
Omeprazole253$4,026
Levothyroxine Sodium278$3,363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$91,72974 claims
Novo NordiskOzempic$315$65,90059 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$46$35,05449 claims
Johnson & JohnsonXarelto$29$32,18121 claims
Boehringer IngelheimJardiance$12$30,18726 claims
AstraZenecaFarxiga$41$17,49912 claims
AbbVieSynthroid$73$1,66033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Daytona Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →